Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
211 hedge funds and large institutions have $1.65B invested in Sage Therapeutics in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 36 closing their positions.
14% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $23.6M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.61% less ownership
Funds ownership: 85.19% → 84.58% (-0.61%)
5% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 74
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
2% less funds holding
Funds holding: 216 → 211 (-5)
22% less capital invested
Capital invested by funds: $2.12B → $1.65B (-$466M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$22.5M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$13.9M |
| 5 |
Morgan Stanley
New York
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$40M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37.3M |
| 3 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
-$13.8M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$10.4M |
| 5 |
AG
Artal Group
Luxembourg
|
-$9.4M |
SAGE Hedge Fund Activity: Q1 2022 in Review
211 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2022, worth a combined $1.65B — down 22% from $2.12B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of SAGE and 34 opened new positions — a net loss of 2 holders — while 74 trimmed existing stakes and 70 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $27.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $40M sold.
- 211 institutional investors held Sage Therapeutics (SAGE) as of Q1 2022, down from 216 in Q4 2021.
- Funds reported $1.65B of Sage Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
- 34 funds opened new Sage Therapeutics positions in Q1 2022 and 36 closed out, a net change of -2 holders.
- The largest Sage Therapeutics buyer in Q1 2022 was T. Rowe Price Associates, an estimated $27.9M added.
- The largest Sage Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $40M sold.
Based on aggregated 13F filings for Q1 2022.